Published in Drugs on December 01, 1996
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother (2009) 1.12
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (2000) 0.81
Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 0.75
Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother (2002) 0.75
Determination of Phenotypic Resistance Cutoffs from Routine Clinical Data. J Acquir Immune Defic Syndr (2016) 0.75
Meloxicam. Drugs (1996) 1.75
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs (1996) 1.53
Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs (1997) 1.46
Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 1.34
Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs (1998) 1.28
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs (1991) 1.25
Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs (1995) 1.24
Fomivirsen. Drugs (1999) 1.13
Azithromycin. A review of its use in paediatric infectious diseases. Drugs (1998) 1.09
Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging (1995) 1.03
Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs (1996) 1.02
Rituximab. Drugs (1999) 0.97
Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs (1995) 0.97
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1996) 0.93
Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability. Drugs (1998) 0.86
Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging (1998) 0.86
Tolterodine. Drugs (1998) 0.83
Levetiracetam. CNS Drugs (1997) 0.82
Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis. Drugs (1995) 0.81
Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging (1997) 0.81
Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs (1994) 0.79
Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs (1994) 0.79
Eprosartan. Drugs (1998) 0.79
Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs (1998) 0.78
Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging (1994) 0.78
Ganirelix. Drugs (2000) 0.77
Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging (1996) 0.77
Ibandronate. Drugs (1999) 0.77
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs (1996) 0.77
Grepafloxacin. Drugs (1997) 0.75
Risedronate. Drugs Aging (1998) 0.75
Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs (1994) 0.75
Xanthogranulomatous pyelonephritis and perirenal xanthogranuloma. Br J Urol (1968) 0.75
Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmacoeconomics (1995) 0.75
Combination hepatitis a-hepatitis B vaccine. BioDrugs (1997) 0.75
Tacalcitol. Drugs (1997) 0.75
[Not Available]. BioDrugs (1997) 0.75
Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection. BioDrugs (1997) 0.75